5-Methyl-3-(piperazin-1-yl)-1,2,4-oxadiazole hydrochloride

Catalog No. :
ACCKYZ693
CAS No. :
1440955-11-2
Molecular Formula :
C7H13ClN4O
Molecular Weight :
204.66

IUPAC Name:5-methyl-3-(piperazin-1-yl)-1,2,4-oxadiazole hydrochloride

5-Methyl-3-(piperazin-1-yl)-1,2,4-oxadiazole hydrochloride structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
50mg95%$54.00Login to see priceInquiryInquiry
100mg95%$93.00Login to see priceInquiryInquiry
250mg95%$133.00Login to see priceIn stockInquiry
1g95%$348.00Login to see priceIn stockInquiry
5g95%$1415.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name5-Methyl-3-(piperazin-1-yl)-1,2,4-oxadiazole hydrochloride
IUPAC Name5-methyl-3-(piperazin-1-yl)-1,2,4-oxadiazole hydrochloride
Molecular FormulaC7H13ClN4O
Molecular Weight204.66
SMILESCC1=NC(N2CCNCC2)=NO1.[H]Cl
InChI KeyKUOKMUKOOXRLQJ-UHFFFAOYSA-N
Synonym1-(5-methyl-1,2,4-oxadiazol-3-yl)piperazine hydrochloride;5-Methyl-3-(piperazin-1-yl)-1,2,4-oxadiazole hydrochloride
CAS No.1440955-11-2

Safety Data

Pictogram
Harmful or irritant
Signal Word
Warning
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P264-P270-P271-P280-P301+P312-P302+P352-P304+P340-P305+P351+P338-P330-P332+P313-P337+P313-P362-P403+P233-P405-P501

Synthetic Route by SureRoute

1. ACCKYZ693 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACEUMO414 route compound structure diagram
    ACEUMO41459813-05-7
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACCKYZ693 route product structure diagram
    ACCKYZ6931440955-11-2 In Stock
Inquiry

2. ACCKYZ693 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACCKYZ693 route product structure diagram
    ACCKYZ6931440955-11-2 In Stock
Inquiry

Comments (0)